The purpose of the study is to determine whether immediate initiation of ART in ART-naïve persons with a CD4+ count >500 cells/mm3 is superior with respect to neurocognitive function to deferring ART initiation until CD4+ counts decline to below 350 cells/mm3.
It is planned to co-enrol a total of 600 participants over 3 years at selected, geographically diverse sites. Randomization (1:1 ratio) to the early or deferred treatment groups will be determined by the START study. Participants will be followed to the common closing date of START.
Updated: 17 Dec 2012